(Q44649838)

5 December 2017

Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness (English)

1 reference

5 December 2017

1 reference

1

Chris T Bauch

1 reference

5 December 2017

Andrea M Anonychuk

2

1 reference

5 December 2017

Thierry Van Effelterre

series ordinal

3

1 reference

5 December 2017

Bá Z Pham

series ordinal

4

1 reference

5 December 2017

Maraki Fikre Merid

series ordinal

5

1 reference

5 December 2017

15 July 2009

1 reference

5 December 2017

Medical Decision Making

1 reference

5 December 2017

29

1 reference

5 December 2017

5

1 reference

5 December 2017

557-569

1 reference

Cost effectiveness of pertussis vaccination in adults

5 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Cost-utility of universal hepatitis A vaccination in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Cost-effectiveness analyses of human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Model for assessing human papillomavirus vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Evaluating human papillomavirus vaccination programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Transients and attractors in epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X09334419

21 January 2018

Identifiers

DOI

10.1177/0272989X09334419

1 reference

5 December 2017

1 reference